Ken Griffin Kal Vista Pharmaceuticals, Inc. Put Options Transaction History

Citadel Advisors LLC

  • $509 Billion
  • Q1 2024

Put Options

4 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2024

May 15, 2024
SELL
$11.07 - $16.04 $12,177 - $17,644
-1,100 Reduced 3.53%
30,100 $356,000
Q4 2023

Feb 14, 2024
BUY
$7.58 - $12.25 $225,126 - $363,825
29,700 Added 1980.0%
31,200 $382,000
Q3 2023

Nov 14, 2023
BUY
$8.95 - $11.35 $13,424 - $17,025
1,500 New
1,500 $14,000
Q4 2022

Feb 14, 2023
BUY
$4.2 - $14.24 $55,860 - $189,392
13,300 New
13,300 $89,000

Others Institutions Holding KALV

# of Institutions
129
Shares Held
46.5M
Call Options Held
113K
Put Options Held
72K
View Full List

About KalVista Pharmaceuticals, Inc.

KALV Quotes by TradingView
  • Ticker KALV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,602,000
  • Market Cap $283M
  • Description
  • KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...
More about KALV
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email